Abivax SA (2X1)
XETR
Real-time Data
07:00 AM
Day's Range
77.5052 wk Range
60.85Overview - 2X1 - Abivax SA
Key Statistics
Valuation
Enterprise Value
6.26B
Price / Book
‪18.20‬
EV / EBITDA
‪-21.49‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-8,617.93%‬
Return on Assets
‪-62.88%‬
Return on Equity
‪-252.34%‬
Ownership
Float
69.02M
Held by Insiders
‪4.17%‬
Held by Institutions
‪50.35%‬
Price stats
Beta
‪-0.24‬
50-Day Avg
‪99.00‬
200-Day Avg
‪101.45‬
Peers - 2X1 - Abivax SA
Peer Comparison
Compared with companies in Biotechnology listed on XETR.
- 2X1XETRAbivax SA+9.19%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- ANLXETRAnalog Devices, Inc.+39.03%52-week change45.97P/E (Trailing)‪29.78%‬Profit Margin
- 0QFXETRModerna Inc.+87.29%52-week change-22.43P/E (Trailing)‪-141.42%‬Profit Margin
- BBZAXETRBB Biotech AG+42.63%52-week change13.32P/E (Trailing)‪127.31%‬Profit Margin
- 7V0XETRDarwin AG+15.00%52-week change140.00P/E (Trailing)‪1.00%‬Profit Margin
- 1AEXETRargenx SE+27.49%52-week change—P/E (Trailing)‪32.26%‬Profit Margin
- 5VAXETRVaxcyte Inc.+18.06%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 2X1 - Abivax SA
About
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, France, and founded in 2013, the company operates in both France and the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
